Novocure completes enrolment in Phase ll trial of TTFields and chemotherapy to treat advanced pancreatic cancer

23rd May 2016 (Last Updated May 23rd, 2016 18:30)

US-based, commercial-stage oncology company Novocure has completed enrolment in a Phase ll trial of tumour treating fields (TTFields) and chemotherapy, PANOVA trial, to treat patients with advanced pancreatic cancer.

Cancer

US-based commercial-stage oncology company Novocure has completed enrolment in a Phase ll trial of tumour treating fields (TTFields) and chemotherapy, PANOVA trial, to treat patients with advanced pancreatic cancer.

A total of 40 patients have been enrolled in the trial and the final data collection date is fixed for six months after the last patient in.

Pancreatic cancer is the fourth leading cause of cancer death in the US and as per the National Cancer Institute estimation, around 48,960 people would be diagnosed with pancreatic cancer and about 40,560 people would die from the disease in 2015.

The single-arm PANOVA trial includes two cohorts of 20 patients with advanced pancreatic cancer whose tumours could not be removed surgically and who had not received prior chemotherapy or radiation therapy.

Novocure had presented data from the first cohort of the trial in January this year.

Data from the first cohort revealed the safety of the combined treatment, and also suggested improved survival and response rate among patients who received TTFields therapy with gemcitabine compared to a historical control of patients who received gemcitabine alone.

In PANOVA, patients who received TTFields therapy, along with first-line gemcitabine, experienced a median progression free survival of 8.3 months compared to 3.7 months for a historical control of gemcitabine alone, and a median overall survival of 14.9 months compared to 6.7 months for a historical control.

Cantonal Hospital senior internist and medical oncologist Dr Marc Kueng said: "The combination with nab-paclitaxel has a strong scientific rationale and is compliant with the current standard of care. We are looking forward to opening a randomised-controlled study testing the efficacy of TTFields in this difficult disease."

The median one-year survival was 55% compared to 22% for a historical control.

"We are looking forward to opening a randomised-controlled study testing the efficacy of TTFields in this difficult disease."

Of the 19 out of 20 evaluable tumours, 30% had partial responses compared to 7% with gemcitabine alone and another 30% had stable disease.

Novocure is planning for a Phase lll clinical trial in pancreatic cancer after obtaining results for the first cohort of PANOVA.

In January last year, the PANOVA trial was expanded to include a second cohort of 20 patients testing TTFields plus gemcitabine and nab-paclitaxel.

Preclinical models have demonstrated increased cancer cell sensitivity when TTFields therapy is combined with taxane-based chemotherapies, including nab-paclitaxel.


Image: Pancreatic cancer is the fourth leading cause of cancer death in the US. Photo: courtesy of Cancer Research UK.